- Advertisement -

a Recently the National Institute of Health Testing highlights the failure of a COVID-19 treatment known as interferon beta-1a, a drug with both antiviral and anti-inflammatory properties, often used as an injection to treat diseases such as multiple sclerosis. is done in.


Separate Small study published in July That made the drug a potential candidate for treating COVID-19, but an NIH study published Monday found that interferon did not benefit the outcomes of adults hospitalized with COVID-19.

- Advertisement -

NIH scientists said that interferon beta-1a has a cellular structure similar to a naturally occurring protein called interferon beta, which is produced by infected cells to help the body’s immune system.

But the researchers found that the use of interferon beta-1a was “not associated with clinical benefit.”

related: Data shows remdesivir reduces risk of COVID-19 hospitalization, Gilead Sciences says

“Laboratory studies have shown that the normal type 1 interferon response is suppressed following infection with SARS-CoV-2, the virus that causes COVID-19,” the researchers said.

The antiviral drug remdesivir was used as an active control in the study. The researchers noted that interferon beta-1a played no role in speeding up the recovery process for hospitalized COVID-19 patients compared to remdesivir.

“The primary outcome, time to recovery, was the same — an average of 5 days — for those receiving interferon beta-1a plus remdesivir for those receiving remdesivir alone,” the researchers wrote.